MIAMI, June 03, 2022 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a leading healthcare services and technology company, announced...
AI-driven discovery platform enables new way to find novel pathways, as well as progress towards identifying patients who may better respond to drugs in...
Ehave owns approximately 9,793,754 shares of Mycotopia Therapies valued at more than $24 million, as of Friday’s closing price; Plans partial distribution...
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – April 21, 2022 – Investment banks are continuing to release positive coverage for psychedelic stocks and the latest report...
MIAMI, April 19, 2022 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a leading healthcare services and technology company, announced...
Agreement with Heally adds doctors, licensed psychotherapists and registered nurses to the KetaDASH platformWith the opening of KetaDASH, Ehave builds...
Ehave has licensed AI technology from Vastmindz for MetaHealthU.in 2022, Ehave plans to monetize the AI technology it licensed from Vastmindz to expand the...
KetaDASH will provide ketamine therapy for the treatment of mental health disordersKetaDASH is a managed service organization focused on the psychedelic...
MIAMI, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a leading healthcare services and technology company, reaffirms...
MIAMI, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Ehave, Inc., (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and...